Global Oncology Market to 2023 – Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic. However, they exert more damage on malignant tissue than healthy tissue due to the rapid cell cycle of cancer cells. The key cancer indications of this report are breast, colorectal, lung, and prostate and hematological cancers.

A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Scope

– Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?

– The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?

– What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications?

– How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?

– What proportion of the key players’ revenues will be attributable to oncology products?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis

- Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players

- Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications

- Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types

- Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers

- Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 10

2.1 Therapy Area Introduction 10

2.2 Symptoms 11

2.3 Diagnosis 12

2.4 Etiology and Pathophysiology 13

2.4.1 Etiology 13

2.4.2 Pathophysiology 15

2.5 Co-morbidities and Complications 16

2.6 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 17

2.6.1 Breast Cancer 17

2.6.2 Colorectal Cancer 18

2.6.3 Lung Cancer 19

2.6.4 Prostate Cancer 20

2.6.5 Hematological Cancers 21

2.7 Prognosis 22

2.7.1 Breast Cancer 22

2.7.2 Colorectal Cancer 23

2.7.3 Non-Small-Cell Lung Cancer 23

2.7.4 Prostate Cancer 24

2.8 Treatment 25

2.8.1 Surgery and Radiation Therapy 25

2.8.2 Chemotherapy 26

2.8.3 Hormonal Therapies 28

2.8.4 Targeted Therapies 29

3 Key Marketed Products 31

3.1 Overview 31

3.2 MabThera/Rituxan (rituximab) 32

3.3 Avastin (bevacizumab) 33

3.4 Herceptin (trastuzumab) 35

3.5 Revlimid (lenalidomide) 37

3.6 Opdivo (nivolumab) 39

3.7 Xtandi (enzalutamide) 41

3.8 Gleevec/Glivec (imatinib mesylate) 42

3.9 Alimta (pemetrexed) 44

3.10 Zytiga (abiraterone acetate) 46

3.11 Conclusion 47

4 Pipeline Landscape Assessment 49

4.1 Overview 49

4.2 Pipeline Development Landscape 50

4.3 Molecular Targets in the Pipeline 54

4.4 Clinical Trials 58

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 58

4.4.2 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target 62

4.4.3 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target 66

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 70

4.4.5 Conclusion 74

4.5 Assessment of Key Pipeline Products 74

4.5.1 Durvalumab - AstraZeneca 74

4.5.2 Durvalumab and Tremelimumab - AstraZeneca 75

4.5.3 Abemaciclib - Eli Lilly 76

4.5.4 Rova-T (rovalpituzumab tesirine) - AbbVie 77

4.5.5 Neratinib - Puma Biotechnology 79

4.5.6 Acalabrutinib - AstraZeneca 80

4.5.7 KTE-C19 (Axicabtagene Ciloleucel) - Kite Pharma 81

4.5.8 Tisagenlecleucel-T - Novartis 83

4.5.9 Conclusion 84

5 Multi-scenario Market Forecast to 2023 85

5.1 Overall Market Size 85

5.2 Generic Penetration 101

5.3 Revenue Forecast by Molecular Target 103

5.3.1 Programmed Cell Death Protein 1/Programmed Cell Death 1 Ligand 1 103

5.3.2 Tumor Necrosis Factor 105

5.3.3 Tyrosine-Protein Kinase BTK 106

5.3.4 Cyclin-Dependent Kinases 107

5.3.5 Androgen Receptor 108

5.3.6 Vascular Endothelial Growth Factor 109

6 Company Analysis and Positioning 110

6.1 Revenue and Market Share Analysis by Company 111

6.1.1 Roche - To What Extent Will Newly Approved and Pipeline Product Approvals Offset the Patent Expiries of Avastin and Herceptin? 116

6.1.2 Celgene - How Will Multiple Patent Expiries Affect Oncology-Related Revenues? 118

6.1.3 Novartis - How Will Mekinist plus Tafinlar and Tasigna Perform over the Forecast Period? 119

6.1.4 Bristol-Myers Squibb - How Successful Will Recent Approvals Opdivo and Empliciti Become? 120

6.1.5 Pfizer - What Do Sutent and Inlyta Patent Expiries Mean for Pfizer? 120

6.1.6 AstraZeneca - How Will its Immune Checkpoint Inhibitors Durvalumab and Tremelimumab Perform? 121

6.2 Company Landscape 123

6.3 Marketed and Pipeline Portfolio Analysis 124

7 Strategic Consolidations 126

7.1 Licensing Deals 126

7.1.1 Deals by Region, Year and Value 126

7.1.2 Deals by Stage of Development and Value 129

7.1.3 Deals by Molecule Type, Mechanism of Action and Value 130

7.1.4 Table for Licensing Deals Valued Above $100m 131

7.2 Co-development Deals 145

7.2.1 Deals by Region, Year and Value 145

7.2.2 Deals by Stage of Development and Value 147

7.2.3 Deals by Molecule Type, Mechanism of Action and Value 148

7.2.4 Table for Co-development Deals Valued $1 billion and Above 149

8 Appendix 156

8.1 References 156

8.2 Abbreviations 417

8.3 Methodology 418

8.3.1 Secondary Research 418

8.3.2 Market Size and Revenue Forecasts 419

8.3.3 Pipeline Analysis 419

8.3.4 Competitive Landscape 419

8.4 Contact Us 420

8.5 Disclaimer 420

List of Tables

1.1 List of Tables

Table 1: Oncology, Global, Symptoms of Key Indication Cancers, 2017 12

Table 2: Complications Associated with Breast, Colorectal, Lung, Prostate and Hematological Cancers 16

Table 3: Oncology, Global, Epidemiology of Key Indication Cancers, 2017 17

Table 4: Oncology Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017 22

Table 5: Oncology Market, US, Colorectal Cancer Stage and Survival Rates (%), 2017 23

Table 6: Oncology Market, US, Lung Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017 24

Table 7: Oncology, US, Prostate Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017 24

Table 8: Optimal and Actual Chemotherapy Usage Rates, 2010 28

Table 9: Oncology Therapeutics Market, Global, Approved Indications for Rituxan, 2017 32

Table 10: Oncology Therapeutics Market, Global, Approved Indications for Avastin, 2017 34

Table 11: Oncology Therapeutics Market, Global, Approved Indications for Herceptin, 2017 36

Table 12: Oncology Therapeutics Market, Global, Approved Indications for Revlimid, 2017 38

Table 13: Oncology Therapeutics Market, Global, Approved Indications for Opdivo, 2017 40

Table 14: Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2017 41

Table 15: Oncology Therapeutics Market, Global, Approved Indications for Gleevec, 2017 43

Table 16: Oncology Therapeutics Market, Global, Approved Indications for Alimta, 2017 45

Table 17: Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2017 46

Table 18: Oncology, Global, Market Size ($bn), 2016-2023 (Part 1) 87

Table 19: Oncology, Global, Market Size ($bn), 2016-2023 (Part 2) 94

Table 20: Oncology, Global, Usage of Generics Across Key Indications, 2017 102

Table 21: Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023 112

Table 22: Oncology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017 131

Table 23: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017 149

Table 24: Oncology, Global, All Pipeline Products, 2017 163

Table 25: Abbreviations 417

List of Figures

1.2 List of Figures

Figure 1: Oncology, Major Markets, Treatment Usage Patterns for Breast Cancer, Patients (millions), 2016-2022 18

Figure 2: Oncology, Major Markets, Treatment Usage Patterns for Colorectal Cancer, Patients (‘000), 2016-2023 19

Figure 3: Oncology, Major Markets, Treatment Usage Patterns for Lung Cancer, Patients (‘000), 2016-2023 20

Figure 4: Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (millions), 2016-2021 21

Figure 5: Oncology, Major Markets, Treatment Usage Patterns for Hematological Cancer, Patients (‘000), 2016-2023 22

Figure 6: Oncology, Global, Key Marketed Products and Approved Indications, 2017 31

Figure 7: Oncology, Global, Annual Revenue for Rituxan ($bn), 2006-2023 33

Figure 8: Oncology, Global, Annual Revenues for Avastin ($bn), 2006-2023 35

Figure 9: Oncology, Global, Annual Revenues for Herceptin ($bn), 2006-2023 37

Figure 10: Oncology, Global, Annual Revenue for Revlimid ($bn), 2006-2023 39

Figure 11: Oncology, Global, Annual Revenues for Opdivo ($bn), 2014-2023 41

Figure 12: Oncology, Global, Annual Revenues for Xtandi ($bn), 2012-2023 42

Figure 13: Oncology, Global, Annual Revenues for Gleevec ($bn), 2006-2023 44

Figure 14: Oncology, Global, Annual Revenues for Alimta ($bn), 2006-2023 46

Figure 15: Oncology, Global, Annual Revenues for Zytiga ($bn), 2011-2023 47

Figure 16: Oncology, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 49

Figure 17: Oncology, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2017 51

Figure 18: Oncology, Global, Pipeline for Key Oncology Indications by Stage of Development, 2017 53

Figure 19: Oncology, Global, Pipeline for Key Oncology Indications by Molecule Type, 2017 54

Figure 20: Oncology, Global, Pipeline for Oncology by Molecular Target, 2017 55

Figure 21: Oncology, Pipeline by Mechanism of Action and Stage of Development, 2017 56

Figure 22: Oncology, Global, Pipeline for Key Oncology Indications by Molecular Target, 2017 57

Figure 23: Oncology, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017 58

Figure 24: Oncology, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017 59

Figure 25: Oncology, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017 60

Figure 26: Oncology, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017 61

Figure 27: Oncology, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 62

Figure 28: Oncology, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017 63

Figure 29: Oncology, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017 64

Figure 30: Oncology, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017 65

Figure 31: Oncology, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017 66

Figure 32: Oncology, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017 67

Figure 33: Oncology, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017 68

Figure 34: Oncology, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017 69

Figure 35: Oncology, Global, Clinical Program Size by Stage of Development (participants), 2006-2017 70

Figure 36: Oncology, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017 71

Figure 37: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017 72

Figure 38: Oncology, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017 73

Figure 39: Oncology, Global, Revenue Forecast for Durvalumab ($bn), 2017-2023 75

Figure 40: Oncology, Global, Revenue Forecast for Durvalumab + Tremelimumab ($bn), 2017-2023 76

Figure 41: Oncology, Global, Revenue Forecast for Abemaciclib ($bn), 2018-2023 77

Figure 42: Oncology, Global, Revenue Forecast for Rova-T ($bn), 2018-2023 79

Figure 43: Oncology, Global, Revenue Forecast for Neratinib ($bn), 2016-2023 80

Figure 44: Oncology, Global, Revenue Forecast for Acalabrutinib ($bn), 2018-2023 81

Figure 45: Oncology, Global, Revenue Forecast for Axicabtagene Ciloleucel ($bn), 2017-2023 82

Figure 46: Oncology, Global, Revenue Forecast for Tisagenlecleucel-T ($bn), 2017-2023 84

Figure 47: Oncology, Global, Market Size ($bn), 2016-2023 86

Figure 48: Oncology, Global, Generic Penetration for Annual Revenue Forecasts ($bn), 2016-2023 101

Figure 49: Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1/ Programmed Cell Death 1 Ligand 1 ($bn), 2016-2023 104

Figure 50: Oncology, Global, Annual Revenue Forecast for Tumor Necrosis Factor ($bn), 2016-2023 105

Figure 51: Oncology, Global, Annual Revenue Forecast for Tyrosine-Protein Kinase BTK ($bn), 2016-2023 106

Figure 52: Oncology, Global, Annual Revenue Forecast for Cyclin-Dependent Kinases ($bn), 2016-2023 107

Figure 53: Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2016-2023 108

Figure 54: Oncology, Global, Annual Revenue Forecast for Vascular Endothelial Growth Factor ($bn), 2016-2023 109

Figure 55: Oncology, Global, Companies by Type, Cluster by Growth and Market Share, 2016-2023 110

Figure 56: Oncology, Global, Company Analysis Matrix, 2017 111

Figure 57: Oncology, Global, Forecast Market Share by Company (%), 2016-2023 114

Figure 58: Oncology, Global, Companies by Compound Annual Growth Rate (%), 2016-2023 115

Figure 59: Oncology, Global, Revenues by Product Type, 2016-2023 116

Figure 60: Oncology, Global, Roche Oncology Annual Revenue Forecast ($bn), 2016-2023 117

Figure 61: Oncology, Global, Celgene Annual Revenue Forecast ($bn), 2016-2023 118

Figure 62: Oncology, Global, Novartis AG Annual Revenue Forecast ($bn), 2016-2023 119

Figure 63: Oncology, Global, Bristol-Myers Annual Revenue Forecast ($bn), 2016-2023 120

Figure 64: Oncology, Global, Pfizer Annual Revenue Forecast ($bn), 2016-2023 121

Figure 65: Oncology, AstraZeneca Annual Revenue Forecast ($bn), 2016-2023 122

Figure 66: Oncology, Global, Companies by Type, 2016-2023 123

Figure 67: Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Oncology Specialization, 2016-2023 124

Figure 68: Oncology, Global, Proportion of Total Company Revenue Attributed to Cancer, 2016-2023 125

Figure 69: Oncology, Global, Licensing Deals, 2006-2017 127

Figure 70: Oncology, Global, Licensing Deals by Indication and Value, 2006-2017 128

Figure 71: Oncology, Global, Licensing Deals by Volume and Value, 2006-2017 129

Figure 72: Oncology, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2017 130

Figure 73: Oncology, Global, Co-development Deals, 2006-2017 145

Figure 74: Oncology, Global, Co-development Deals by Indication and Value, 2006-2017 146

Figure 75: Oncology, Global, Co-development Deals by Volume and Value, 2006-2017 147

Figure 76: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017 148

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports